12月22日,齐鲁制药旗下恩他卡朋双多巴片(Ⅱ)(申可安)在阿里健康首发。该药适用于治疗经左旋多巴/多巴脱羧酶抑制剂疗法未能控制的“剂末”运动功能波动的成人帕金森病患者。我国65岁以上人群帕金森病患病率约1.7%,患者总数超300万,长期接受左旋多巴治疗的患者易出现“剂末现象”,严重影响生活质量。申可安整合三种成分制成单一复方片剂,可提高左旋多巴入脑水平,延长其半衰期,减轻外周不良反应,简化用药...
Source Link12月22日,齐鲁制药旗下恩他卡朋双多巴片(Ⅱ)(申可安)在阿里健康首发。该药适用于治疗经左旋多巴/多巴脱羧酶抑制剂疗法未能控制的“剂末”运动功能波动的成人帕金森病患者。我国65岁以上人群帕金森病患病率约1.7%,患者总数超300万,长期接受左旋多巴治疗的患者易出现“剂末现象”,严重影响生活质量。申可安整合三种成分制成单一复方片剂,可提高左旋多巴入脑水平,延长其半衰期,减轻外周不良反应,简化用药...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.